Bernie Sanders poised to steer FDA user fee renewal, could push for reforms

Democrats' midterm victory may shape the upcoming negotiations on the Prescription Drug User Fee Act, which funds the FDA's review of medicines.

Senator Bernie Sanders, a longtime critic of the user‑fee system, is expected to lead the Senate health committee and influence the legislation.

Sanders could use the renewal process, due before Sept. 30, to advocate for reforms that reduce the agency's reliance on industry fees.

Any changes to the fee structure could affect the FDA's budget and its ability to approve new drugs, a concern for pharmaceutical companies and investors.